Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable…
ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB Technology
BERLIN and BALTIMORE, Oct. 29, 2025 /PRNewswire/ -- ICHORtec GmbH is pleased to announce an expanded research collaboration…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…